Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug…
Technology, History, Art & Companies
Explore the main themes, entities and connections around MorphoSys. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
company development antibody clinical us novartis tafasitamab 2020 ag inc developed proprietary dr pipeline nasdaq otilimab license agreement treatment drug
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| MorphoSys | Founded | 1992; 34 years ago (1992) | 1.00 | infobox |
| MorphoSys | Headquarters | Planegg, Upper Bavaria, Germany | 1.00 | infobox |
| MorphoSys | Industry | Biotechnology | 1.00 | infobox |
| MorphoSys | Key people | Dr. Jean-Paul Kress (CEO) Sung Lee (CFO) Dr. Malte Peters (Chief Research & Development Officer) Dr. Roland Wandeler (CCO) Dr. Marc Cluzel (chairman of Supervisory Board) | 1.00 | infobox |
| MorphoSys | Net income | €97.9 million (2020) | 1.00 | infobox |
| MorphoSys | Number of employees | 615 (end 2020) | 1.00 | infobox |
| MorphoSys | Operating income | €27.4 million (2020) | 1.00 | infobox |
| MorphoSys | Parent | Novartis | 1.00 | infobox |
| MorphoSys | Products | Immunotherapy | 1.00 | infobox |
| MorphoSys | Revenue | €327.7 million (2020) | 1.00 | infobox |
| MorphoSys | Total assets | €1,659.5 million (end 2020) | 1.00 | infobox |
| MorphoSys | Total equity | €621.3 million (end 2020) | 1.00 | infobox |
| MorphoSys | Traded as | FWB: MOR | 1.00 | infobox |
| MorphoSys | Traded as | Nasdaq: MOR | 1.00 | infobox |
| MorphoSys | Type | Public | 1.00 | infobox |
| MorphoSys | Website | morphosys.com | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.